Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 9084782
Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
granted -
US 9084762
T-cell immunogens derived from anti-viral proteins and methods of using same
granted -
US 9084746
Therapeutic applications of SMAD7
granted -
US 9079944
Influenza A virus vaccines and inhibitors
granted -
US 9078881
Salinosporamides and methods of use thereof
granted -
US 9079913
Spiro-oxindole MDM2 antagonists
granted -
US 9078441
Antimicrobial flush solutions
granted -
US 9080148
Neuronal cells cultured on microparticles and methods of using the neuronal cells
granted -
US 9078922
Metal-organic frameworks with exceptionally large pore aperatures
granted -
US 9078919
Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair
granted -
US 9072732
Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease
granted -
US 9072705
Oligo-benzamide compounds and their use in treating cancers
granted -
US 9072765
Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
granted -
US 9073985
Methods and products for treating proliferative diseases
granted -
US 9073980
Tumor selective E1a and E1b mutants
granted -
US 9073974
RGD-containing cyclic peptides
granted -
US 9073863
Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
granted -
US 9073851
Compositions and methods for treating cancer
granted -
US 9072792
Peptides whose uptake by cells is controllable
granted -
US 9073884
Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them
granted -
US 9068007
Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
granted -
US 9068002
Treatment of multiple sclerosis and/or rheumatoid arthritis
granted -
US 9067968
Tight junction protein modulators and uses thereof
granted -
US 9067961
Thiocarbon-protecting groups for RNA synthesis
granted -
US 9066900
Interferon-Ξ² production modulating listeria strains and methods for using same
granted -
US 9066943
Use of botulinum toxin therapy for treatment of urological neurological conditions
granted -
US 9066883
Administration of cells and cellular extracts for rejuvenation
granted -
US 9066855
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
granted -
US 9062288
Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
granted -
US 9063125
Compositions comprising cells expressing cold- and menthol-sensitive receptor (CMR1) polypeptides
granted -
US 9062297
Yersinia pestis vaccine
granted -
US 9062093
Peptide compositions and methods for treating patients
granted -
US 9061071
Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
granted -
US 9061055
Oncolytic adenovirus armed with therapeutic genes
granted -
US 9061048
Cyclic di-AMP induction of type I interferon
granted -
US 9061027
Enhanced delivery of drug compositions to treat life threatening infections
granted -
US 9062347
Endothelin single nucleotide polymorphisms and methods of predicting Ξ²-adrenergic receptor targeting agent efficacy
granted -
US 9057054
Antigen-specific long-term memory T-cells
granted -
US 9056924
Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
granted -
US 9056087
Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
granted -
US 9056102
VEGF-activated trail ligands
granted -
US 9051550
Cellular seeding and co-culture of a three dimensional fibroblast construct
granted -
US 9050378
N2S2 chelate-targeting ligand conjugates
granted -
US 9050376
Conjugates of synthetic TLR agonists and uses therefor
granted -
US 9050372
High molecular weight derivatives of vitamin K-dependent polypeptides
granted -
US 9050299
Administration of growth factors for the treatment of CNS disorders
granted -
US 9050298
Method of treating ischemia/reperfusion injuries to a heart with netrin-1
granted -
US 9044381
Method for delivering drugs to the brain
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory